Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer January 17, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology January 17, 2023
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology & Immunology Targets January 17, 2023
Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Companion Diagnostic for XPOVIO® (selinexor) January 17, 2023
Lurbinectedin “Named Patient Program” for Small-Cell Lung Cancer launched in Hong Kong January 17, 2023
Enrollment in Ph 1 Trial of ADXS-504 for the Treatment of Early Prostate cancer completed January 17, 2023
Enrollment in Ph 2 Clinical Trial MN-166 (ibudilast) trial in Recurrent and Newly Diagnosed Glioblastoma patients completed January 17, 2023
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer January 17, 2023
Promising Top-Line Results from Ph 2 Trial of BXCL701 in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) patients announced January 17, 2023
Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrated Meaningful Responses with Tovorafenib (DAY101) in Pediatric Low-Grade Glioma January 17, 2023
Upcoming 2023 Readouts from Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib announced January 17, 2023
Results from Ph 1 dose-expansion study of STRO-002 (luvelta) in patients with advanced ovarian cancer announced January 17, 2023
Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer January 17, 2023
IND approved for MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor Cancers January 17, 2023
